In my last column, I mentioned that I had an intrathecal baclofen pump. I’d make a bad pun, but I don’t have it in me. Spasticity, spasms, and hyperreflexivity were some of my first symptoms, which steadily got worse as my multiple sclerosis (MS) progressed.

So, where was I last week? I was in the midst of writing this column when I was felled overnight by my long-term nemesis: a urinary tract infection (UTI). As usual, I had no idea I had one — but hey, I was ill. I’m sure I’ve banged on…

Editor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum post “Need advice about CBD oil,” published on Nov. 1, 2018. Share your…

Sativex (nabiximols) eases spasticity-associated symptoms in multiple sclerosis (MS) patients, including those with no significant improvements in a validated spasticity scale, according to a large study from Italy. The findings support previous studies suggesting that spasticity scales may not be enough to evaluate patients’ responses to Sativex and to…

Topline results of an exploratory Phase 2 clinical trial revealed that Flex Pharma‘s treatment candidate FLX-787 improves muscle cramps, spasms and muscle stiffness in patients with multiple sclerosis (MS). The double-blinded trial, conducted in Australia, evaluated an oral dose of 19 mg FLX-787, taken twice daily in liquid…

Flex Pharma has completed enrolling multiple sclerosis patients in a Phase 2 clinical trial in Australia testing FLX-787’s ability to alleviate muscle stiffness, spasms, and cramps. The compound has a mechanism of action that Flex believe will generate fewer side effects than other muscle-relaxing medications. The company is also…

Multiple sclerosis is so weird. Sometimes I just put up with a strange sensation or painful problem because I do not know how to describe it to the doctor without sounding crazy. I hope the problems will just go away, and sometimes they do. Maybe I am a little…

Flex Pharma, Inc., announced the start of a Phase 2 clinical trial assessing the safety and efficacy of FLX-787 in multiple sclerosis (MS) patients who suffer from cramps, spasms, and/or spasticity as a result of the disease. The trial is being run in conjunction with Neuroscience Trials Australia. Flex Pharma’s FLX-787 is a single molecule,…